Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Hydroxyzine Use and Mortality in Patients Hospitalized for COVID-19: A Multicenter Observational Study

Marina Sánchez-Rico 1 Frédéric Limosin 2 Raphaël Vernet 3 Nathanaël Beeker 4 Antoine Neuraz 5 Carlos Blanco 6 Mark Olfson 7 Cédric Lemogne 3 Pierre Meneton 8 Christel Daniel 9, 8 Nicolas Paris 9 Alexandre Gramfort 10 Guillaume Lemaitre 11 Pedro de la Muela Elisa Salamanca 9 Mélodie Bernaux 9 Ali Bellamine 9 Anita Burgun 12 Nicolas Hoertel 2
1 IPNP - U1266 Inserm - Institut de psychiatrie et neurosciences de Paris
2 Hôpital Corentin Celton [Issy-les-Moulineaux]
3 HEGP - Hôpital Européen Georges Pompidou [APHP]
4 Hôpital Cochin [AP-HP]
5 Service d'informatique médicale et biostatistiques [CHU Necker]
6 National Institute on Drug Abuse [Bethesda]
7 Columbia University [New York]
8 LIMICS - Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé
9 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
10 CEA - CEA- Saclay
11 DGD-I - Direction générale déléguée à l'innovation
12 CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers
Abstract : Background: Based on its antiviral activity, anti-inflammatory properties, and functional inhibition effects on the acid sphingomyelinase/ceramide system (FIASMA), we sought to examine the potential usefulness of the H1 antihistamine hydroxyzine in patients hospitalized for COVID-19. (2) Methods: In a multicenter observational study, we included 15,103 adults hospitalized for COVID-19, of which 164 (1.1%) received hydroxyzine within the first 48 h of hospitalization, administered orally at a median daily dose of 25.0 mg (SD = 29.5). We compared mortality rates between patients who received hydroxyzine at hospital admission and those who did not, using a multivariable logistic regression model adjusting for patients’ characteristics, medical conditions, and use of other medications. (3) Results: This analysis showed a significant association between hydroxyzine use and reduced mortality (AOR, 0.51; 95%CI, 0.29–0.88, p = 0.016). This association was similar in multiple sensitivity analyses. (4) Conclusions: In this retrospective observational multicenter study, the use of the FIASMA hydroxyzine was associated with reduced mortality in patients hospitalized for COVID-19. Double-blind placebo-controlled randomized clinical trials of hydroxyzine for COVID-19 are needed to confirm these results, as are studies to examine the potential usefulness of this medication for outpatients and as post-exposure prophylaxis for individuals at high risk for severe COVID-19.
Keywords : COVID-19 SARS-CoV-2 hydroxyzine FIASMA treatment inpatients mortality death
Type de document :
Article dans une revue
Liste complète des métadonnées
https://hal.sorbonne-universite.fr/hal-03519439
Contributeur : Hal Sorbonne Université 5 Gestionnaire Connectez-vous pour contacter le contributeur
Soumis le : lundi 10 janvier 2022 - 14:41:27
Dernière modification le : jeudi 7 avril 2022 - 13:58:21
Archivage à long terme le : : lundi 11 avril 2022 - 23:13:50

Fichier

Vignette du document
jcm-10-05891.pdf
Publication financée par une institution

Identifiants

Collections

SORBONNE-UNIVERSITE | PSL | CORDELIERS | CEA | LIMICS | EPHE | SORBONNE-PARIS-NORD | UP-SANTE | SU-SCIENCES | INRIA | SU-TI | UNIV-PARIS13 | UNIV-PARIS

Citation

Marina Sánchez-Rico, Frédéric Limosin, Raphaël Vernet, Nathanaël Beeker, Antoine Neuraz, et al.. Hydroxyzine Use and Mortality in Patients Hospitalized for COVID-19: A Multicenter Observational Study. Journal of Clinical Medicine, MDPI, 2021, 10 (24), pp.5891. ⟨10.3390/jcm10245891⟩. ⟨hal-03519439⟩

Exporter

BibTeX TEI DC DCterms EndNote Datacite

Partager

Métriques

Consultations de la notice

29

Téléchargements de fichiers

29